During the corresponding time, Tempus Ai Inc recorded a revenue increase by 36.12 % year on year, sequentially revenue fell by -5.2 %. While revenue at the Tempus Ai Inc 's corporate clients
Tempus Ai Inc's Comment on Sales, Marketing and Customers
The company’s business is influenced by factors including the acceptance of its publications, implementation of business models, competition, and potential disruption by Intelligent Diagnostics. It focuses on expanding sales to existing and new customers while navigating macroeconomic impacts, reimbursement strategies, intellectual property management, government regulation, regulatory filings, personnel considerations, and international expansion. Notably, the company has established a joint venture, SB Tempus Corp., in Japan and has acquired Ambry Genetics Corporation, Deep 6 AI, Inc., and Paige.AI, Inc. The company also manages debt obligations, litigation, financing needs, and addresses market trends and challenges. Customers and markets referenced in filings include Ambry Genetics Corporation, Deep 6 AI, Inc., Paige.AI, Inc., and SB Tempus Corp.
Tempus AI Enlists Top Physicians to Revolutionize Oncology Research with New Advisory Board Tempus AI, Inc. (NASDAQ: TEM), a Chicago-based leader in AI-driven precision medicine, has made a significant stride in advancing oncology research through the establishment of a distinguished advisory board. This move marks a pivotal moment as the company continues to forge a path towards more individualized and effective patient care.Launched with a clear vision in mind on April 18, 2025, the Tempus Advisory Board is composed of some of the most reputable physicians from across the United States. This cadre of medical experts is poised to deliver strategic advice and guidance, ensuring that Tempus s AI-driven resear...
Precision Medicine Revolution: Tempus AI s Groundbreaking Exhibitions at the 2025 American College of Cardiology Annual Meeting In the rapidly evolving domain of precision medicine, Tempus AI, Inc. (NASDAQ: TEM) stands as a pioneering force bridging the worlds of artificial intelligence (AI) and healthcare. In a significant stride towards revolutionizing patient care, the company is set to debut four pivotal research abstracts at the forthcoming American College of Cardiology (ACC) Annual Meeting in Chicago. This marks a landmark occasion for Tempus, as it presents its research findings at this prestigious convention for the first time, underlining its commitment to advancing the integration of AI in precisi...
Tempus AI to Present Groundbreaking Research at the 2024 Society for Immunotherapy of Cancer Annual Meeting Tempus AI, Inc. (NASDAQ: TEM), at the forefront of integrating artificial intelligence in precision medicine, has taken a significant step forward with the announcement that nine of its abstracts have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting. This esteemed event is scheduled to take place in Houston, Texas, from November 6 to 10, 2024, bringing together some of the most notable minds in the field of cancer immunotherapy.The acceptance of these abstracts underscores Tempus’s commitment to leveraging cutting-edge AI technologies t...
Tempus AI: Advancing Precision Medicine with New AMA Code and FDA Clearances Tempus AI, Inc. (NASDAQ: TEM), a pioneering entity in artificial intelligence and precision medicine, has announced several critical milestones that underline its leadership and innovative capabilities in the healthcare sector. From receiving a unique PLA code for its PurISTSM algorithmic test to obtaining FDA clearance for its AI-based ECG device, Tempus continues to drive transformative changes in medical diagnostics and patient care. Further, the company has entered into a significant collaboration with United Therapeutics to leverage AI for detecting pulmonary hypertension. This article delves into these groundbreaking develop...
Tempus and United Therapeutics Collaborate to Pioneer AI-based Detection of Pulmonary Hypertension RiskTempus AI, Inc., a renowned player in the artificial intelligence (AI) and precision medicine sector, has recently unveiled its collaboration with United Therapeutics, a prominent biotechnology company known for its breakthroughs in novel pharmaceuticals and technologies. The primary aim of this collaboration is to develop innovative AI-powered medical device software with the capability to detect patients who may be at risk of undiagnosed pulmonary hypertension.Pulmonary hypertension is a complex and potentially life-threatening condition characterized by high blood pressure in the lungs arteries. It ofte...
Tempus Ai Inc’s Comment on Sales, Marketing and Customers
The company’s business is influenced by factors including the acceptance of its publications, implementation of business models, competition, and potential disruption by Intelligent Diagnostics. It focuses on expanding sales to existing and new customers while navigating macroeconomic impacts, reimbursement strategies, intellectual property management, government regulation, regulatory filings, personnel considerations, and international expansion. Notably, the company has established a joint venture, SB Tempus Corp., in Japan and has acquired Ambry Genetics Corporation, Deep 6 AI, Inc., and Paige.AI, Inc. The company also manages debt obligations, litigation, financing needs, and addresses market trends and challenges. Customers and markets referenced in filings include Ambry Genetics Corporation, Deep 6 AI, Inc., Paige.AI, Inc., and SB Tempus Corp.
Sources:
Tempus Ai Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tempus Ai Inc’s corporate clients.
For your research, we’ve provided 9 tables on Tempus Ai Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
